TGFB1 and neoplasm: TGF-β has been identified as a major cytokine within a tumor that skews neutrophil differentiation toward the N2 phenotype [16, 18, 19], while TGF-β blockade and type-1 IFN (α, β, ω) treatment are known to shift the balance toward the N1 phenotype [20, 21].